AKT1 and metastatic malignant neoplasm: An open-label, multicenter, Phase Ib dose-escalation combination study using a 3 + 3 design of GDC-0068 (Genentech Inc., South San Francisco, CA, USA), a novel oral selective ATP-competitive AKT inhibitor targeting P13k-Akt-mTOR pathway in metastatic cancer refractory to standard therapy enrolled 23 patients in the GDC-0068 + docetaxel (Taxotere, Sanofi-Aventis, Paris, France) arm and is ongoing.